Nancy Whiting
Company: Seattle Genetics
Job title: Executive Vice President, Late Stage Development
Seminars:
Live Discussion & Question Time 10:00 am
day: Day One
PADCEV: An Evolution in the Therapeutic Landscape of Urothelial Cancer 9:20 am
• Assessing ADCs as a new therapeutic class in bladder cancer and PADCEV’s unique mechanism of action • Analyzing data on efficacy/safety of PADCEV in metastatic urothelial cancer and ongoing exploration of its activity in early bladder cancer • Evaluating PADCEV as an MMAE-class ADC and its potential synergy with immunotherapyRead more
day: Day One